GSK will pay $110 million upfront to license Hutchmed’s HMPL-A830, a preclinical KRAS/EGFR antibody conjugate designed for dual pathway blockade. Under the terms, GSK gets ex-China rights and could make additional payments totaling up to $1.295 billion, plus royalties tied to net sales. The molecule links an anti-EGFR antibody to a KRAS inhibitor payload with the intent to concentrate the cytotoxic activity in EGFR-expressing tumors while also suppressing EGFR/KRAS signaling. The structure of the deal—preclinical to Phase I with a later handoff—highlights how large pharma is using licensing to move quickly into prioritized oncology targets without building all discovery and early development in-house.